The generated graphs (Figure 1D) illustrated that, in breast, kidney, liver, and prostate cancers, ECT2 was significantly upregulated in tumor tissues versus normal ones, a trend that was kept when we set a comparison between ECT2 expression in tumor tissues versus metastatic ones. This evidence concerns the gene ECT2 and Familial prostate cancer.